A series of novel monobactam inhibitors of human cytomegalovirus (HCMV) protease has been described that possess a heterocyclic thiomethyl side chain at C-4. Changes to the heterocycle did not significantly change the inhibitory activity of these compounds in an enzymatic assay, although improvements in solubility and cell culture activity were noted. A number of permutations between C-4 substitu-tions and N-1 derivatives led to the identification of several β β-lactams with antiviral activity in a plaque reduction assay. N-methyl thiotetrazole-containing compounds were found to be the most potent inhibitors in the enzymatic assay.
Human cytomegalovirus (HCMV), a member of the family Herperviridae, infects a large percentage of the general population (Gold & Nankervis, 1982) . This virus is an opportunistic pathogen in immunocompromised individuals such as AIDS patients and organ transplant recipients, and can cause significant morbidity and mortality (Alford & Britt, 1993) . Current therapies for HCMV infection mainly target the viral DNA polymerase, but these drugs show suboptimal efficacy and safety profiles (Markham & Faulds, 1994; Wagstaff et al., 1994) . HCMV, like all herpesviruses, encodes a protease that is essential for viral replication. Inhibition of this enzyme has become an attractive target for antiviral chemotherapy (Gibson et al., 1994; Holwerda, 1997) .
HCMV protease is a serine protease, which is expressed as part of a larger precursor together with the viral capsid assembly protein. Autoproteolytic cleavage of the 85 kDa precursor protein at the R site (amino acid 256) releases the 28 kDa N-terminal catalytic domain (N o ) (Welch et al., 1993; Stevens et al., 1994; Holwerda et al., 1994) . Processing of the assembly protein at the M site located near the C terminus (amino acid 643) by the protease is essential for DNA encapsidation and the production of mature infectious virions (Preston et al., 1992; Gao et al., 1994) .
HCMV protease has little similarity with other serine proteases (Rawlings & Barrett, 1994) . Biochemical studies have identified Ser-132 and His-63 as two residues involved in the catalytic machinery (Gibson et al., 1994; Holwerda, 1997) . Recent reports of the crystal structure of HCMV protease (Tong et al., 1996; Qiu et al., 1996; Shieh et al., 1996; Chen et al., 1996) , have identified the third member of the triad as His 157, and have shown that the protease possesses a novel protein fold. It has recently been reported that 4-thioalkyl-β-lactams are potent HCMV protease inhibitors (Déziel & Malenfant, 1998; Borthwick et al., 1998) . Our rationale in choosing the β-lactam nucleus was based on the knowledge that many β-lactam derivatives are inhibitors of classical serine proteases such as human leukocyte elastase (Finke et al., 1995) . Although HCMV protease was effectively inhibited, the 4-thioalkyl-β-lactam derivatives did not have the required stability in cell culture for good antiviral activity. Further to this study, we described novel monobactams bearing a benzyl group at C-4 and a tetrasubstituted urea at N-1, which had improved stabilities in cell culture (Yoakim et al., 1998) . These compounds were modestly active in a plaque reduction assay despite their low micromolar potency in an enzymatic assay. We report herein the design and synthesis of new β-lactam derivatives that are potent and selective inhibitors of HCMV protease.
Introduction

Materials and Methods: Chemistry
General methods and sources
Unless otherwise noted, materials obtained from commercial sources were used without further purification. All reactions were carried out under inert atmosphere. In the last step, the reactions were performed on approximately 100 mg scale to give the reported yields. 1 H NMR spectra were obtained on a Bruker AMX 400 spectrometer with tetramethylsilane as an internal standard (δ scale) and in the given solvent. FAB mass spectra were recorded on an Autospec VG spectrometer. ES mass spectra were recorded on a Quattro II spectrometer. Column chromatography was performed either on silica gel (10-40 µm or 230-400 mesh ASTM, Merck) or by preparative HPLC using a Partisil 10 ODS-3, C 18 preparative column (50 cm×22 mm). Analytical HPLC was carried out in the following systems: system A, Vydac C 18 , 10 mm analytical column (24 cm×4.6 mm), mobile phase, acetonitrile/0.06% trifluoroacetic acid (TFA) in water/0.06% TFA: system B, Vydac C 18 , 10 mm analytical column (24 cm×4.6 mm); mobile phase, acetonitrile in 20 mM aqueous Na 2 HPO 4 pH 8.2. A full listing of spectral and analytical data is available as supplementary material from the Editor-in-Chief on request.
1-(tert-Butyldimethylsilyl)-4(R)-(hydroxymethyl)azetidin-2-one (2)
To a solution of 1-(tert-butyldimethylsilyl)-4-oxoazeti-dine-2(R)-carboxylic acid (1) (Finke et al., 1995; Baldwin et al., 1990) (15.0 g, 65.4 mmol) in THF (367 ml) at 0°C was added N-methylmorpholine (7.2 ml, 65 mmol) and isobutyl chloroformate (8.5 ml, 65 mmol). After stirring for 1.5 h at 0°C, a solution of NaBH 4 (9.9 g, 261 mmol) in H 2 O (98 ml) was added portion-wise (caution: vigorous gas evolution and foaming). The reaction was stirred for 45 min, then diluted with EtOAc and quenched with aqueous HCl solution (10%) to pH 5-6. The organic phase was collected and the aqueous phase was extracted twice with EtOAc. The combined organic layers were washed with saturated aqueous NaHCO 3 and brine, dried (MgSO 4 ), filtered and concentrated. The residual oil was purified by flash chromatography (gradient 25% to 50% EtOAc:hexane) to give 2 (8.46 g, 60% yield) as a white solid. 1 H NMR (CDCl 3 ) δ 3.74-3.69 (m, 1H), 3.65-3.56 (m, 2H), 3.10-2.98 (m, 1H), 2.81-2.76 (m, 1H), 2.01 (s, 1H), 0.89 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H); IR (KBr) ν 3723, 1733 cm -1 ; FAB MS m/z 216.2 (MH + ); Anal. calcd for C 10 H 21 NOSi: C, 55.77; H, 9.83; N, 6.50. Found: C, 55.79; H, 9.90; N, 6.38. General procedure for the Mitsunobu reaction leading to compounds (3a-3i)
To a solution of 2 (2.75 g, 12.8 mmol) in THF (80 ml) was added PPh 3 (6.70 g, 25.5 mmol). The reaction was cooled to 0°C and DEAD (3.30 ml, 25.5 mmol) was added dropwise. After 5 min, 2-mercaptopyrimidine (3.60 g, 31.9 mmol) was added. After stirring for 15 min at 0°C and 24 h at room temperature, the reaction mixture was concentrated. The residue was treated with EtOAc:hexane (1:1) and the resulting solid was filtered and rinsed with Et 2 O. The filtrate was concentrated and purified by flash chromatography (25% EtOAc:hexane) to provide 3b ( General procedure for ureido formation
To a solution of 4a (80.7 mg, 0.42 mmol) in THF (6 ml) at -20°C, lithium bis(trimethylsilyl)amide (420 µl, 1 M in THF) was added. After 10 min the reaction was cooled to -78°C and 1(R)-phenylethyl isocyanate (90 µl, 0.63 mmol) was added. Stirring was continued at -78°C for 5 min, then continued at room temperature for 30 min. The reaction mixture was diluted with EtOAc and washed with aqueous NH 4 Cl (10%) and brine, dried (MgSO 4 ), filtered and concentrated. The residue was purified by flash chromatography (20% EtOAc in hexane) to give 5 (91 mg, 64% yield) as a white solid. HPLC 100% (system A), 
N-Methyl-1(R)-phenylpropyl-1-carbamoyl chloride (8)
To a solution of 1(R)-phenylpropylamine (6) (1.1 g, 8.4 mmol) in CH 2 Cl 2 (40 ml) at 0°C was added DIEA (2.0 ml, 11.7 mmol) and 2,2,2-trichloroethyl chloroformate (1.5 ml, 10 mmol). The reaction was stirred for 1 h at room temperature and then the solvent was evaporated. The resulting residue was triturated with Et 2 O (50 ml), filtered through a silica gel plug which was washed with 50% EtOAc in hexane (100 ml). The combined filtrates were concentrated in vacuo. The resulting yellow oil was dissolved in THF (10 ml) and cooled to 0°C. A solution of A solution of 7 in CH 2 Cl 2 was cooled to 0°C. DIEA (1.0 ml, 6.2 mmol) was introduced, followed by a solution of phosgene in toluene (1.93 M, 3.5 ml, 6.8 mmol). After 1 h at 0°C, the reaction mixture was concentrated and the resulting residue was extracted with Et 2 O. Evaporation of the Et 2 O extract gave an oil which was purified by flash chromatography (10% EtOAc in hexane) to give 8 (0.8 g, 80% yield) as a clear oil. 1 H NMR (CDCl 3 , mixture of rotamers) δ 7.24-7.13 (m, 5H), 5.31 (m, 1H), 2.67, 2.59 (2bs, 3H), 2.03-1.77 (m, 2H), 0.91-0.85 (m, 3H).
N-Boc-N-benzyl-3-chloropropylamine (10)
To a solution of 3-chloropropylamine hydrochloride (9) (10 g, 77 mmol) and aqueous NaOH (10 M, 7.6 ml, 76 mmol) in THF (50 ml) was added di-tert-butyldicarbonate (16 g, 73 mmol) in THF (10 ml) followed by a mixture of MeOH/H 2 O (30 ml, 2/1 ml). The resulting solution was stirred for 2 h, then concentrated to approximately 15 ml and Et 2 O was added. The organic phase was washed twice with aqueous HCl (1.0 M), water and brine, dried (MgSO 4 ), filtered and concentrated to give N-Boc-3chloropropylamine (14.2 g, 96% yield) as a yellow oil. 1 H NMR (CDCl 3 ) δ 4.70 (m, 1H), 3.59 (t, J 6.3 Hz, 2H), 3.25 (m, 2H), 1.91 (m, 2H), 1.42 (s, 9H).
To a solution of N-Boc-3-chloropropylamine (10.0 g, 51.8 mmol) in THF (200 ml) was added sodium hydride (1.9 g, 78 mmol). After 20 min, benzyl bromide (9.2 ml, 78 mmol) was added and the reaction mixture was heated at reflux for 16 h. After cooling, the reaction mixture was diluted with Et 2 O (150 ml) and H 2 O (50 ml), the layers were separated and the aqueous layer was extracted twice with Et 2 O. The combined organic phases were washed with H 2 O and brine, dried (MgSO 4 ), filtered and concentrated. The resulting yellow oil was purified by flash chromatography (10% EtOAc in hexane) to give 10 (1.97 g, 13% yield) as a pale yellow oil. 1 H NMR (CDCl 3 ) δ 7.29-7.19 (m, 5H), 4.40 (bs, 2H), 3.45 (bm, 2H), 3.25 (bm, 2H), 1.90 (bm, 2H), 1.44, 1.39 (2s, 9H).
2-Phenylpyrrolidine-1-carboxylic acid tert-butyl ester (11a)
To a solution of tetramethylethylenediamine (0.83 ml, 5.47 mmol) and n-BuLi (1.6 M hexane, 3.3 ml, 5.3 mmol) cooled to -78°C was added dropwise a solution of 10 (1.0 g, 3.5 mmol) in THF (5 ml). The resulting yellow solution was stirred at -78 °C for 5 h. The reaction mixture was then quenched with aqueous NH 4 Cl (20 ml) and diluted with Et 2 O (150 ml), the layers were separated and the aqueous layer was extracted twice with Et 2 O. The combined organic phases were washed with H 2 O and brine, dried (MgSO 4 ), filtered and concentrated. The resulting yellow oil was purified by flash chromatography (10% EtOAc in hexane) to give 11a (0.57 g, 65% yield). 1 H NMR (CDCl 3 ) δ 7.31-7.14 (m, 5H), 4.90-4.71 (m, 1H), 3.59 (m, 2H), 2.29 (m, 1H), 1.92-1.84 (m, 3H), 1.43, 1.16 (2s, 9H). Alternatively, by replacing tetramethylethylenediamine with (-)-sparteine and THF with toluene, compound 11b was obtained in 51% yield (Beak et al., 1994) .
2-phenylpyrrolidine-1-carbamoyl chloride (12a or 12b)
A solution of 11a or 11b (0.55 g, 2.23 mmol) in HCl/dioxane (4 M, 5 ml) was stirred for 30 min then evaporated to dryness. To the resulting oil was added CH 2 Cl 2 (25 ml) and DIEA (0.90 ml, 5.13 mmol), and the mixture was cooled to 0°C. Phosgene (1.93 M in toluene, 1.62 ml, 3.12 mmol) was added rapidly, and the reaction mixture was stirred for 1 h and then concentrated. The resulting solid was extracted with Et 2 O and the undissolved residue was filtered and discarded. The ethereal solution was concentrated and the resulting oil was purified by flash chromatography (10% EtOAc in hexane) to give 12a or 12b (0.43 g, 85% yield). Biological assays IC 50 and EC 50 values were determined by previously published methods (Yoakim et al., 1998; Ogilvie et al., 1997; Bonneau et al., 1998) . Each reported IC 50 value represents the mean of at least three determinations. The reproducibility of the enzymatic assay was gauged using Ac-Gly-Tbg-Val-Asn-Ala(CF 3 ) as a standard. This compound gave an IC 50 of 8.14±0.29 (95% confidence limit based on 2s m ) on 291 determinations. Ganciclovir was used as a positive control in the plaque reduction assay and gave an EC 50 of 1.23±0.07 µM (95% confidence limit based on 2s m ) on 82 determinations. The cytotoxicity of drugs was deterned with the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) (Denizot & Lang, 1986) under the same cell culture assay conditions used in the plaque reduction assay.
Computational methods
Semi-empirical quantum mechanical calculations were performed with Spartan 5.0.1 (Wavefunction, Irvine, Calif., USA) using the AM1 hamiltonian (Dewar et al., 1985) . A systematic search was performed by rotating the N-C urea-benzyl single bond in 15°increments with a point energy calculated. The lowest energy positions were then submitted for full minimization.
Results
Chemistry
The methods used to synthesize the inhibitors are summarized in Figs 1 to 4. Fig. 1 illustrates the general procedure for attaching various heterocyclic substituents to the C-4 position of the β-lactam nucleus. Carboxylic acid 1 (Finke et al., 1995) was prepared according to known procedures (Baldwin et al., 1990 ) from D-aspartic acid. Reduction of 1 was achieved via the formation of a mixed anhydride using isobutylchloroformate in the presence of N-methylmorpholine followed by treatment with sodium borohydride (Rodriguez et al., 1991) to give alcohol 2 in 60% yield. Conversion of alcohol 2 into thioether derivatives 3a-i was achieved using the Mitsunobu protocol (Hughes, 1992; Dormoy, 1982) . Subsequent deprotection with caesium fluoride in methanol gave the corresponding β-lactams 4a-i, suitable for further elaboration. Fig. 2 illustrates the general procedure used for the introduction of the ureido group. Deprotonation of 4a with LiHMDS in THF, followed by addition of 1(R)phenylethyl isocyanate or 1(R)-phenylpropyl isocyanate, gave the ureido compounds 5 in 64% yield.
Isocyanates and carbamoyl chlorides that were not commercially available were prepared as previously reported (Yoakim et al., 1998) . The secondary amines required for the formation of carbamoyl chlorides were easily made by condensation of the appropriate benzyl halide with methylamine (Yoakim et al., 1998) . Carbamoyl chlorides, which could not readily be prepared by this protocol, were synthesized as described (Figs 3 and 4) . 1-(R)-Phenylpropyl amine (6, Fig. 3 ) was methylated via reduction of the 2,2,2trichloroethyl carbamate to give 7 in 63% overall yield. Reaction with phosgene in the presence of diisopropylethylamine (DIEA) gave carbamoyl chloride 8 (92%). Pyrrolidines such as 12 were obtained as shown in Fig. 4 . 3-Chloropropyl amine (9) was protected as the Boc derivative, which was treated with sodium hydride and benzyl bromide in THF to give compound 10 in 13% yield. Cyclization of this intermediate was accomplished using n-BuLi in the presence of tetramethylethylenediamine (Beak et al., 1994) to afford racemic pyrrolidine 11a in 65% yield. Alternatively, the deprotonation was carried out using (-)sparteine and n-BuLi in toluene (Wu et al., 1996) to give the S-isomer 11b in 51% yield. Deprotection and carbamoyl chloride formation as described above gave the expected compounds 12a and 12b, respectively.
Discussion
We have recently reported the development of 4-thioalkylβ-lactams as inhibitors of HCMV protease (Déziel & Malenfant, 1998) . Furthermore, we have shown that it is not necessary to attach a hetero-atom directly to C-4 of the β-lactam ring to generate potent inhibitors of HCMV protease. Indeed, monobactams bearing a carbon appendage at C-4, most notably a benzyl substituent, were effective HCMV protease inhibitors with improved stabilities in cell culture relative to the 4-thioalkyl series (Yoakim et al., 1998) . However, the optimization of pharmacophores at this position in the C-4 carbon series required a new side chain design to allow for the introduction of a variety of substituents. A consideration of previous results identified compound 13 (Déziel & Malenfant, 1998) (Table 1) as a potent inhibitor of HCMV protease that could be a suitable template for redesign. Reversing the thiomethylene linker at C-4 to give derivatives such as 5 would alleviate the synthetic problems inherent in the all carbon series and provide rapid access to a large number of derivatives, providing that activity could be maintained. As shown in Table  1 (entry 2), this modification gave a compound that was only 1.8-fold less active than 13, indicating that the strategy was viable. A simple extension of the 1-(R)-phenylethyl substituent on the exocyclic urea gave inhibitor 14 with potency comparable to that of compound 13 (Table 1; entry 3). The structure-activity relationship based on compound 14 began with the use of the thioether linkage to introduce a variety of heterocycles. As shown in Table 2 , a number of heterocycles were examined with no major impact on the inhibitory activity in the enzymatic assay. IC 50 values ranging from 6.3 µM for the 2-pyridyl derivative (15) to 2.0 µM for the 4-pyridyl analogue (16) were obtained, indicating that the enzyme was very permissive towards substituents at this position.
We therefore turned to the N-1 side chain as a means of increasing the activity of the inhibitors (Table 3) . We had previously observed (Yoakim et al., 1998) that the configuration of an asymmetric centre introduced into the urea appendage could have a strong influence on the activity of the compounds. In the present series, it was found that an inhibitor incorporating a simple benzyl urea was eight times less active than was the corresponding (R)-1-phenylpropyl compound (17) ( Table 3 ; entries 1 and 2). Inverting the configuration of the benzylic side chain reduced the potency of the monobactams by a factor of six (Table 3 ; entries 2 and 3). Interestingly, there was only a 1.6-fold difference in the activity of the epimeric ureas when the nitrogen was methylated (Table 3 ; entries 4 and 5). In fact, it was apparent that the use of such a chiral appendage was deleterious in the tetrasubstituted urea series (entries 4 to 6). The reason for this may be a change in conformational space available to compounds 25 and 26 relative to 17 and 24.
In order to investigate this hypothesis we carried out a series of calculations on analogues of compounds 17, 24, 25 and 26. The C-4 substituent was modelled as a simple benzyl group, oriented antiperiplanar to the β-lactam nitrogen ring, to simplify the calculations. Consistent with NMR evidence, no exocyclic amide (urea) rotation was considered. The low energy conformers for the (R)-or (S)-ethyl substituted benzyl ureas were investigated by semi-empirical (AM1) methods. Individual rotamers of the urea substituent were located by a systematic search followed by local minimization. These AM1 calculations reproduced well the crystal structure of a related HCMV inhibitor ( Fig. 5) (Yoakim et al., 1998) . When the crystal structure was calculated by AM1, the overall (all heavy atoms except the SCF 3 substituent) r.m.s. deviation was 0.43 Å, the all heavy atom only r.m.s. deviation was 0.62 Å, and the core (β-lactam plus the heavy atoms of the urea out to and including the benzylic position of the N-benzyl group) was 0.12 Å. The larger deviation in the first two cases was due to small rotations of the C-4 benzyl and SCF 3 groups. The results of these calculations indicate that the urea side chains of compounds 17 and 24 are essentially locked in a conformation in which the urea carbonyl and the benzylic C-H bond are antiperiplanar (see supplementary material, available from the Editor-in Chief on request, for energies). This conformational locking may lead to a difference in activity for the two epimers 17 and 24, as well as an improvement in potency relative to the unsubstituted case (23) (Yoakim et al., 1998) . The calculations performed on the R and S ethyl substituted compounds in the Nmethyl series identified two rotamers for each compound (see supplementary material, available from the Editor-in Chief on request, for dihedral angles). The structures of these rotamers deviated significantly from those of the N-H series. Calculations also show that N-methylation forces the urea carbonyl out of the plane of the β-lactam ring. This difference in conformational preference and overall urea structure of 25 and 26 relative to 17 and 24 may account for the different patterns in the inhibitory data observed for each series.
In order to try to exploit the conformational locking inherent in compounds such as 17, cyclic analogues 28 and 29 were prepared. By reducing the conformational space available, small differences in activity were noted (Table 3; entries 7 and 8), although an improvement in activity relative to 17 was not realized.
In a previous study, we had noted that N-methyl-Nbenzyl-substituted ureas incorporating strong electron withdrawing groups at the para position of the phenyl ring gave improvements in the activity of the monobactam compounds (Yoakim et al., 1998) . A series of inhibitors were therefore made incorporating the best urea substituents together with the 2-pyrimidinylthiomethyl moiety at C-4 ( Table 4 ). As previously noted, the use of trifluoromethyl or nitro groups gave the best activities (Table 4 ; entries 3 and 6). Other electron withdrawing functions gave smaller improvements relative to compound 27 (Table  4 ; entries 2, 4 and 5).
So far, it had been established that many heterocycles were acceptable on the C-4 side chain of the β-lactam ring ( Table 2) , and that SAR was consistent regarding substitution at N-1 (Table 4 ). In order to find the best combination of substituents, a number of permutations were prepared that led to the identification of two N-methyl thiotetrazole compounds having interesting activities (Table 5) . Indeed, for the first time, compounds were made that showed submicromolar potency in the enzymatic assay. Furthermore, these inhibitors had interesting activity in a plaque reduction assay. N-methyl thiotetrazole 35 exhibited the best overall profile between the plaque reduction assay (Yoakim et al., 1998; Ogilvie et al., 1997 ) (EC 50 ) and cell toxicity (TC 50 ). Both compounds (35 and 36) were selective for HCMV protease as exemplified by at least a 50-fold difference in IC 50 versus HLE. Selectivity was also measured against porcine pancreatic elastase, bovine pancreatic αchymotrypsin, and human liver cathepsin B (all IC 50 >60 µM). The antiviral activity of these compounds was correlated with the inhibition of the protease-dependent processing of the protease precursor and the assembly protein in a cell-based assay (Dô et al., 1997) . In this assay, the inhibition of processing of the assembly and precursor proteins by the protease could be monitored inside infected cells. This method has been used to show that compounds 35 and 36 penetrate into cells and inhibit HCMV protease. Details of this assay, along with a complete description of the results obtained with a number of inhibitors from several structural classes will be disclosed elsewhere. A series of novel monobactam inhibitors of HCMV protease has been described that possess a heterocyclic thiomethyl side chain at C-4. Changes to the heterocycle did not change significantly the enzymatic activity of these compounds. A number of permutations between C-4 substitution and N-1 derivatives led to the identification of several β-lactams with antiviral activity in a plaque reduction assay. N-methyl thiotetrazole-containing compounds (35 and 36) were found to be the most potent in the enzymatic assay. Furthermore, these compounds exhibited antiviral activity in a plaque reduction assay and cell-based assay. performed the enzymatic assay. Thanks to L Lagacé and MJ Massariol for the preparation of the recombinant enzymes used in this study, and to D Wernic for the synthesis of the substrates used in the enzymatic assay. The plaque reduction assay was performed by N Dansereau, M Liuzzi and A-M Bonneau. The crystallographic structure used to support the AM1 results was obtained by L Tong. 
